Literature DB >> 6840171

Pharmacokinetics of metoprolol and its metabolite alpha-OH-metoprolol in healthy, non-smoking, elderly individuals.

C G Regårdh, S Landahl, M Larsson, P Lundborg, B Steen, K J Hoffmann, P O Lagerström.   

Abstract

The absorption and disposition of metoprolol have been evaluated in 10 healthy, non-smoking, elderly individuals (mean age 73.1 years) by simultaneous determination of [3H]-metoprolol and unlabelled metoprolol. The labelled drug was given as an intravenous tracer dose, immediately followed by oral metoprolol 25 mg. The experiment was preceded by administration of metoprolol 25 mg b.i.d. for 3 days. The volume of distribution, elimination half-life and total body clearance were almost the same as previously observed in healthy, young subjects. The mean systemic availability was about 39% in the elderly, which is lower than the mean of 55% observed in a control group of young volunteers who received 50 mg b.i.d. In the elderly, the mean plasma concentration of alpha-OH-metoprolol was about twice as high as that of the parent drug, whereas the opposite was true of the control group. The results indicate that age-related physiological changes have a negligible effect on the pharmacokinetics of metoprolol.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6840171     DOI: 10.1007/bf00613821

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  22 in total

1.  Effects of age and cigarette smoking on propranolol disposition.

Authors:  R E Vestal; A J Wood; R A Branch; D G Shand; G R Wilkinson
Journal:  Clin Pharmacol Ther       Date:  1979-07       Impact factor: 6.875

2.  Plasma concentrations and beta-blocking effects in normal volunteers after intravenous doses of metoprolol and propranolol.

Authors:  C G Regårdh; G Johnsson; L Jordö; P Lungborg; B A Persson; O Rönn
Journal:  J Cardiovasc Pharmacol       Date:  1980 Nov-Dec       Impact factor: 3.105

3.  Biological determinants of propranolol disposition in man.

Authors:  D M Kornhauser; A J Wood; R E Vestal; G R Wilkinson; R A Branch; D G Shand
Journal:  Clin Pharmacol Ther       Date:  1978-02       Impact factor: 6.875

4.  Pharmacokinetic studies on the selective beta1-receptor antagonist metoprolol in man.

Authors:  C G Regårdh; K O Borg; R Johansson; G Johnsson; L Palmer
Journal:  J Pharmacokinet Biopharm       Date:  1974-08

5.  Effect of age on plasma propranolol levels.

Authors:  R E Schneider; H Bishop; R A Yates; C P Quarterman; M J Kendall
Journal:  Br J Clin Pharmacol       Date:  1980-08       Impact factor: 4.335

6.  A simple method for the determination of glomerular filtration rate.

Authors:  J Bröchner-Mortensen
Journal:  Scand J Clin Lab Invest       Date:  1972-11       Impact factor: 1.713

7.  Plasma levels and effect on heart rate and blood pressure of metoprolol after acute oral administration in 12 geriatric patients.

Authors:  P Lundborg; B Steen
Journal:  Acta Med Scand       Date:  1976

8.  The effect of impaired renal function on the plasma concentration and urinary excretion of metoprolol metabolites.

Authors:  K J Hoffmann; C G Regårdh; M Aurell; M Ervik; L Jordö
Journal:  Clin Pharmacokinet       Date:  1980 Mar-Apr       Impact factor: 6.447

9.  Selected ion monitoring of metoprolol and two metabolites in plasma and urine using deuterated internal standards.

Authors:  M Ervik; K J Hoffmann; K Kylberg-Hanssen
Journal:  Biomed Mass Spectrom       Date:  1981-07

10.  Pharmacokinetic and pharmacodynamic properties of metoprolol in patients with impaired renal function.

Authors:  L Jordö; P O Attman; M Aurell; L Johansson; G Johnsson; C G Regårdh
Journal:  Clin Pharmacokinet       Date:  1980 Mar-Apr       Impact factor: 6.447

View more
  27 in total

Review 1.  Hepatic drug metabolism and aging.

Authors:  C Durnas; C M Loi; B J Cusack
Journal:  Clin Pharmacokinet       Date:  1990-11       Impact factor: 6.447

Review 2.  Required beta blocker profile in the elderly.

Authors:  L H Opie
Journal:  Cardiovasc Drugs Ther       Date:  1991-01       Impact factor: 3.727

3.  Prediction of modified release pharmacokinetics and pharmacodynamics from in vitro, immediate release, and intravenous data.

Authors:  Viera Lukacova; Walter S Woltosz; Michael B Bolger
Journal:  AAPS J       Date:  2009-05-09       Impact factor: 4.009

4.  Subjective symptoms and pharmacokinetics/dynamics of metoprolol CR in elderly subjects--a comparison with atenolol.

Authors:  E S Dimenäs; C G Dahlöf; B Heibel; R G Moore; B K Olofsson; G E Westergren; P W Lücker
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

Review 5.  The pharmacokinetics of non-steroidal anti-inflammatory drugs in the elderly.

Authors:  K W Woodhouse; H Wynne
Journal:  Clin Pharmacokinet       Date:  1987-02       Impact factor: 6.447

Review 6.  The polymorphic oxidation of beta-adrenoceptor antagonists. Clinical pharmacokinetic considerations.

Authors:  M S Lennard; G T Tucker; H F Woods
Journal:  Clin Pharmacokinet       Date:  1986 Jan-Feb       Impact factor: 6.447

7.  Pharmacokinetics of metoprolol during pregnancy and lactation.

Authors:  Rachel J Ryu; Sara Eyal; Thomas R Easterling; Steve N Caritis; Raman Venkataraman; Gary Hankins; Erik Rytting; Kenneth Thummel; Edward J Kelly; Linda Risler; Brian Phillips; Matthew T Honaker; Danny D Shen; Mary F Hebert
Journal:  J Clin Pharmacol       Date:  2015-12-04       Impact factor: 3.126

8.  Physiologically Based Pharmacokinetic Modelling to Identify Pharmacokinetic Parameters Driving Drug Exposure Changes in the Elderly.

Authors:  Felix Stader; Hannah Kinvig; Melissa A Penny; Manuel Battegay; Marco Siccardi; Catia Marzolini
Journal:  Clin Pharmacokinet       Date:  2020-03       Impact factor: 6.447

9.  A comparison of the pharmacokinetics of atenolol, metoprolol, oxprenolol and propranolol in elderly hypertensive and young healthy subjects.

Authors:  J W Rigby; A K Scott; G M Hawksworth; J C Petrie
Journal:  Br J Clin Pharmacol       Date:  1985-10       Impact factor: 4.335

10.  Receptor occupancy in lumbar CSF as a measure of the antagonist activity of atenolol, metoprolol and propranolol in the CNS.

Authors:  T Kaila; R Marttila
Journal:  Br J Clin Pharmacol       Date:  1993-05       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.